MedTrace Logo

INSPIRE: INnovative SABR for Prostate Cancer All IREland

NCT07552168 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-06-01

No results posted yet for this study

Summary

This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. Eligible patients will receive next generation prostate SABR incorporating toxicity reduction strategies

Conditions

  • Prostate Adenocarcinoma

Interventions

RADIATION

Next generation Stereotactic Ablative Radiotherapy (SABR)

Treatment will prioritise the dominant intraprostatic lesion (DIL) while sparing surrounding organs at risk (OARs).

Sponsors & Collaborators

  • Cancer Trials Ireland

    lead NETWORK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2030-09-30
Completion
2034-11-30

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07552168 on ClinicalTrials.gov